U.S. markets closed
  • S&P Futures

    3,929.50
    +7.00 (+0.18%)
     
  • Dow Futures

    32,005.00
    +89.00 (+0.28%)
     
  • Nasdaq Futures

    13,318.25
    +16.25 (+0.12%)
     
  • Russell 2000 Futures

    2,297.90
    +12.80 (+0.56%)
     
  • Crude Oil

    63.36
    +0.14 (+0.22%)
     
  • Gold

    1,794.70
    -3.20 (-0.18%)
     
  • Silver

    28.06
    +0.20 (+0.70%)
     
  • EUR/USD

    1.2171
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4140
    -0.0001 (-0.01%)
     
  • USD/JPY

    105.9950
    +0.1130 (+0.11%)
     
  • BTC-USD

    50,371.08
    +181.61 (+0.36%)
     
  • CMC Crypto 200

    1,004.71
    -10.20 (-1.01%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,156.48
    +484.78 (+1.63%)
     

Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Sarepta Therapeutics, Inc. SRPT was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $82.29 –$178.74 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Sarepta currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Sarepta Therapeutics, Inc. Price

Sarepta Therapeutics, Inc. Price
Sarepta Therapeutics, Inc. Price


Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Halozyme Therapeutics, Inc. HALO, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report
 
Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.